P134 SARS-CoV-2 infection in cystic fibrosis during the first pandemic wave in Italy: a multi-centre prospective study with a control group

Seroprevalence of SARS-CoV-2 IgG in people with cystic fibrosis

“…In Europe, during the first wave of the pandemic, people with cystic fibrosis were more frequently hospitalized due to SARS-CoV-2 infection than the age matched general population [ 7 ], however, the underlying seroprevalence within the CF community has not been well described and infection fatality rate can only be poorly estimated [ 8 , 9 ]. In Italy, one study demonstrated 64 out of 434 CF patients >12 years of age had positive SARS-CoV-2 spike antibody levels (pre vaccine era) with over half of these patients being asymptomatic suggesting a much higher prevalence within the population than previously thought [ 10 ]. With the advent of COVID-19 vaccines, describing the prevalence of antibody formation within this population that relies on primary prevention is of utmost importance.…”